Literature DB >> 21350859

Defining care products to finance health care in the Netherlands.

Machiel Westerdijk1, Joost Zuurbier, Martijn Ludwig, Sarah Prins.   

Abstract

A case-mix project started in the Netherlands with the primary goal to define a complete set of health care products for hospitals. The definition of the product structure was completed 4 years later. The results are currently being used for billing purposes. This paper focuses on the methodology and techniques that were developed and applied in order to define the casemix product structure. The central research question was how to develop a manageable product structure, i.e., a limited set of hospital products, with acceptable cost homogeneity. For this purpose, a data warehouse with approximately 1.5 million patient records from 27 hospitals was build up over a period of 3 years. The data associated with each patient consist of a large number of a priori independent parameters describing the resource utilization in different stages of the treatment process, e.g., activities in the operating theatre, the lab and the radiology department. Because of the complexity of the database, it was necessary to apply advanced data analysis techniques. The full analyses process that starts from the database and ends up with a product definition consists of four basic analyses steps. Each of these steps has revealed interesting insights. This paper describes each step in some detail and presents the major results of each step. The result consists of 687 product groups for 24 medical specialties used for billing purposes.

Entities:  

Mesh:

Year:  2011        PMID: 21350859      PMCID: PMC3286594          DOI: 10.1007/s10198-011-0302-6

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  7 in total

Review 1.  Strategic hospital alliances: do the type and market structure of strategic hospital alliances matter?

Authors:  M J McCue; J P Clement; R D Luke
Journal:  Med Care       Date:  1999-10       Impact factor: 2.983

2.  Using computerised patient-level costing data for setting DRG weights: the Victorian (Australia) cost weight studies.

Authors:  T Jackson
Journal:  Health Policy       Date:  2001-05       Impact factor: 2.980

3.  The risk of upcoding in casemix systems: a comparative study.

Authors:  Paul J M Steinbusch; Jan B Oostenbrink; Joost J Zuurbier; Frans J M Schaepkens
Journal:  Health Policy       Date:  2006-08-14       Impact factor: 2.980

4.  Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries.

Authors:  Jonas Schreyögg; Tom Stargardt; Oliver Tiemann; Reinhard Busse
Journal:  Health Care Manag Sci       Date:  2006-08

5.  A portfolio approach to strategic hospital analysis: exposition and explanation.

Authors:  M Drain; L Godkin
Journal:  Health Care Manage Rev       Date:  1996

6.  Casemix-based funding of Northern Territory public hospitals: adjusting for severity and socio-economic variations.

Authors:  C Beaver; Y Zhao; S McDermid; D Hindle
Journal:  Health Econ       Date:  1998-02       Impact factor: 3.046

7.  One DRG, one price? The effect of patient condition on price variation within DRGs and across hospitals.

Authors:  W J Lynk
Journal:  Int J Health Care Finance Econ       Date:  2001-06
  7 in total
  8 in total

1.  Payment schemes and treatment responses after a demand shock in mental health care.

Authors:  Rudy Douven; Minke Remmerswaal; Tobias Vervliet
Journal:  Health Econ       Date:  2021-09-07       Impact factor: 2.395

2.  Prevalence of interstitial and other lung diseases on Aruba.

Authors:  Deenstra Duco; Wolvetang Niek; Kock Selene; Wills Stuart; Cobben Nicolle; Wijnen Petal; Drent Marjolein
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

3.  Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands.

Authors:  Rudy Douven; Monique Burger; Frederik Schut
Journal:  Health Econ Policy Law       Date:  2019-04-11

4.  Prices and market power in mental health care: Evidence from a major policy change in the Netherlands.

Authors:  Chiara Brouns; Rudy Douven; Ron Kemp
Journal:  Health Econ       Date:  2021-01-27       Impact factor: 3.046

5.  Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population.

Authors:  Manon J M van Oosten; Dan Koning; Susan J J Logtenberg; Martijn J H Leegte; Henk J G Bilo; Marc H Hemmelder; Kitty J Jager; Vianda S Stel
Journal:  Clin Kidney J       Date:  2021-12-03

6.  Financial risk allocation and provider incentives in hospital-insurer contracts in The Netherlands.

Authors:  Chandeni S Gajadien; Peter J G Dohmen; Frank Eijkenaar; Frederik T Schut; Erik M van Raaij; Richard Heijink
Journal:  Eur J Health Econ       Date:  2022-04-12

7.  Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls.

Authors:  Manon J M van Oosten; Susan J J Logtenberg; Marc H Hemmelder; Martijn J H Leegte; Henk J G Bilo; Kitty J Jager; Vianda S Stel
Journal:  Clin Kidney J       Date:  2021-07-06

8.  The validity of Dutch health claims data for identifying patients with chronic kidney disease: a hospital-based study in the Netherlands.

Authors:  Manon J M van Oosten; Richard M Brohet; Susan J J Logtenberg; Anneke Kramer; Lambert D Dikkeschei; Marc H Hemmelder; Henk J G Bilo; Kitty J Jager; Vianda S Stel
Journal:  Clin Kidney J       Date:  2020-11-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.